We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck and Ridgeback Biotherapeutics have said their experimental COVID-19 antiviral MK-4482 (molnupiravir) significantly reduced infection after five days of treatment in a clinical trial. Read More
According to Lilly, tirzepatide reduced blood sugar levels by 2.09 percent at 5 mg, 2.37 percent at 10 mg and 2.46 percent at 15 mg, vs. 1.86 percent for 1 mg of Ozempic. Read More
The UK’s RECOVERY trial, which is assessing multiple potential COVID-19 treatments, has stopped enrollment in its arm evaluating colchicine, an anti-inflammatory drug used to treat gout. Read More
Merck’s anti-parasitic drug Stromectol (ivermectin) did not help speed recovery in patients with mild COVID-19, researchers in Cali, Colombia, found in a small clinical trial. Read More
“While we are disappointed with the recommendation … We are encouraged by the safety profile of VIR-7831 and by the possibility of a benefit on top of remdesivir and corticosteroids in this advanced cohort of patients,” said Vir Biotechnology CEO George Scangos. Read More
Worldwide trials of the shot have shown wide variations in efficacy rates, and the company has faced criticism for a lack of transparency regarding its trial findings. Read More
Eli Lilly said its investigational drug, tirzepatide, reduced blood sugar and body weight in adults with type 2 diabetes significantly more than Novo Nordisk’s blockbuster Ozempic (semaglutide), in a head-to-head clinical study. Read More
Indian drugmaker Bharat Biotech has announced that its COVID-19 vaccine candidate, Covaxin (BBV152), proved to be 80.6 percent effective in the initial interim analysis of its late-stage clinical trials. Read More
Merck is planning to launch a new late-stage trial of an experimental COVID-19 treatment, MK-7110 (CD24Fc), because the previous phase 3 study enrolled too few participants to support regulatory clearance from the FDA. Read More
The new biologic drug improved lung function in patients, helped control asthma better and cut the risk of hospitalizations or emergency visits by 79 percent, trial data showed. Read More
The UK analysis showed that 0.8 percent of unvaccinated healthcare workers tested positive, while only 0.2 percent of vaccinated workers were positive 12 or more days after receiving a single dose. Read More